方法：采用德国SCHWIND公司生产的AMARIS准分子激光系统，对进行全激光TransPRK术的80例156眼近视患者，进行裸眼远视力、矫正视力、屈光度、眼压、角膜地形图、干眼等随访，观察分析。

结果：随访1a，裸眼远视力≥1.0者47例92眼，占58.8%。裸眼远视力0.8者20例40眼，占25%； 裸眼远视力0.6者13例24眼，占16.3%。接近或高于最佳矫正视力(BCVA)者63例121眼，占78.8%。稍低于最佳矫正视力(BCVA)1行或2行者17例34眼，占21.2%。术后干眼9例18眼，占11.3%。主诉有眩光，夜间视力差16例32眼，占20%。

结论：准分子全激光TransPRK术是治疗近视、散光的安全、有效的理想表层手术方式之一。术后远视力及屈光度稳定，手术安全性好。

METHODS: Eighty myopic cases(156 eyes)with or without astigmatism were treated by TransPRK. In all eyes, treatments were planned with Custom Ablation Manager Software and ablations performed with the SCHWIND AMARIS system. Clinical outcomes of visual acuity, manifest refraction, intraocular pressure, and corneal topography were observed and analyzed. The follow-up period was one year.

RESULTS: All patients completed the 1-year follow-up. After one-year follow-up, 47 cases(92 eyes, 58.8%)achieved an uncorrected distance visual acuity(UDVA)≥1.0. Twenty cases(40 eyes, 25%)was 0.8 and 13 cases(24 eyes, 16.3%)was 0.6. Sixty-three cases(121 eyes, 78.8%)were close to or above best corrected visual acuity(BCVA). Seventeen cases(34 eyes, 21.2%)were slightly lower than BCVA 1 row or two. Nine cases(18 eyes, 11.3%)got dry eye postoperatively. 16 cases(32 eyes, 20%)complain of glare and poor night vision.

CONCLUSION: The results show that TransPRK for myopia with or without astigmatism is safe and effective. The postoperative visual outcomes are stable.